Investigators have implemented an automated health maintenance tool created by the National Kidney Foundation into electronic medical records to prompt primary care physicians to screen for chronic kidney… read more.
Renalytix plc announces that the FDA has granted De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. This affirms KidneyIntelX as a first-in-class, artificial intelligence enabled prognostic testing… read more.
When a patient with chronic kidney disease finally reaches the point that their kidneys fail, doctors have a treatment available: dialysis. But undergoing dialysis often brings a high burden of other… read more.
Jesduvroq (daprodustat) from GSK received a positive opinion from the CHMP for the treatment of adult patients for for the treatment of symptomatic anaemia in adults with chronic… read more.
In a new study looking at the long-term effects of hospitalized patients who have acute kidney injury (AKI), a sudden but temporary loss of kidney function, Johns Hopkins… read more.
A study of kidney organoids in a novel lab environment might have downstream implications for the treatment of polycystic kidney disease (PKD), an incurable condition that affects more than… read more.
A serious condition that can cause the kidneys to suddenly stop working could be treated with existing medicines, a new study shows. In a study in mice scientists… read more.
Early diagnosis of chronic kidney disease (CKD) is key to managing progression of the disease. A new technique analyzing urine extracellular vesicles (uEVs) — cell-derived nanoscale spherical structures… read more.
The findings suggest that methods developed in high-income settings to check kidney function are not accurate for many people in Africa. Researchers from the African Research on Kidney… read more.
A new algorithm developed by researchers at Columbia University can analyze thousands of variants across the genome and estimate a person’s risk of developing chronic kidney disease —… read more.
GlaxoSmithKline plc announced that the European Medicines Agency (EMA) validated the marketing authorisation application (MAA) for daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the… read more.
Researchers report that patients diagnosed with type 2 diabetes in their youth are, by young adulthood, at risk of serious complications. The findings from the TODAY2 study (Treatment… read more.